Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development
Arie Regev, Naga Chalasani(Indiana University – Purdue University Indianapolis), James W. Freston(University of Connecticut), John M. Vierling(Baylor College of Medicine), Adrian M. Di Bisceglie(Saint Louis University), Ethan Miller(The University of Texas MD Anderson Cancer Center), Jack Uetrecht(University of Toronto), Mark Avigan(United States Food and Drug Administration), Niti Patel(Takeda (United States)), Robert J. Fontana(University of Michigan), Herbert L. Bonkovsky(Atrium Health Wake Forest Baptist), Alexandre Kiazand(AstraZeneca (United States)), Stephanie O. Omokaro(United States Food and Drug Administration), Gerd A. Kullak‐Ublick(University Hospital of Zurich), Hewei Li(Bristol-Myers Squibb (United States)), James H. Lewis(Georgetown University), Paul B. Watkins(University of North Carolina Health Care), Karen Price(Purchase College), Meenal Patwardhan(AbbVie (United States)), Nonko Pehlivanov(Janssen (United States)), Melanie J. Harrison(Bristol-Myers Squibb (United States)), Syed Asif Haque(AstraZeneca (United States))
Cited by 79
Related Papers
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
|Hepatology|2017|7.2k
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
|JNCI Journal of the National Cancer Institute|2008|1.7k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
|New England Journal of Medicine|2021|1.1k